Real-world Outcomes of Anti–Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema in the United States
[ad_1] Recently co-authored a retrospective study of nearly 16,000 patients with diabetic macular edema (DME), a common cause of visual impairment: At 1 year, despite treatment, real-world DME patients have meaningfully worse visual outcomes compared to patients in randomized controlled trials, and those with well-preserved …